How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy
- PMID: 16735667
- DOI: 10.1345/aph.1G534
How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy
Abstract
Objective: To review the evidence on adherence with bisphosphonates and evolving dosing strategies for osteoporosis treatment.
Data sources: Articles were identified by searching MEDLINE (1975-December 2005) using the following terms: osteoporosis, postmenopausal, fracture, adherence, compliance, persistence, drug therapy, bisphosphonates, alendronate, risedronate, ibandronate, and zoledronate. Additional data included bibliographies from identified articles.
Study selection and data extraction: All pertinent English-language articles that discussed adherence issues in patients with osteoporosis were included. Both those that reviewed overall issues of medication adherence in osteoporosis and those that focused specifically on adherence to bisphosphonates were included, as were articles that addressed strategies for overcoming nonadherence.
Data synthesis: Inadequate diagnosis and treatment of osteoporosis result in a higher risk of fractures than is necessary. Even patients who are diagnosed and beginning treatment often do not persist with their osteoporosis medication because they perceive their fracture risk to be low and, given the asymptomatic nature of osteoporosis, do not experience the benefit of symptom reduction after taking the drugs. Factors that affect adherence to osteoporosis therapy include drug costs, adverse effects, dosing frequency, disease education, patient follow-up, and patient involvement in treatment decisions.
Conclusions: By considering and implementing strategies that can improve adherence and persistence, primary care providers and pharmacists (via counseling) may enhance long-term outcomes for patients with osteoporosis.
Similar articles
-
The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.Curr Med Res Opin. 2007 Dec;23(12):3137-52. doi: 10.1185/030079907X242890. Curr Med Res Opin. 2007. PMID: 17988435
-
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019. Am J Med. 2006. PMID: 16563937 Review.
-
Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.Clin Ther. 2007 Jun;29(6):1116-27. doi: 10.1016/j.clinthera.2007.06.009. Clin Ther. 2007. PMID: 17692726 Review.
-
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27. Ann Pharmacother. 2008. PMID: 18505912
-
Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Postgrad Med. 2011. PMID: 21474901 Review.
Cited by
-
Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture.Ther Adv Musculoskelet Dis. 2009 Feb;1(1):5-11. doi: 10.1177/1759720X09339551. Ther Adv Musculoskelet Dis. 2009. PMID: 22870423 Free PMC article.
-
A review of patient-centred post-fracture interventions in the context of theories of health behaviour change.Osteoporos Int. 2011 Aug;22(8):2213-24. doi: 10.1007/s00198-010-1521-x. Epub 2011 Jan 11. Osteoporos Int. 2011. PMID: 21305267
-
Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.BMC Musculoskelet Disord. 2013 Sep 23;14:276. doi: 10.1186/1471-2474-14-276. BMC Musculoskelet Disord. 2013. PMID: 24060442 Free PMC article.
-
A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients.Oncol Rev. 2012 Jun 13;6(1):e5. doi: 10.4081/oncol.2012.e5. eCollection 2012 Mar 5. Oncol Rev. 2012. PMID: 25992207 Free PMC article. Review.
-
Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study.Int J Med Sci. 2013 Nov 20;10(13):1880-7. doi: 10.7150/ijms.5359. eCollection 2013. Int J Med Sci. 2013. PMID: 24324365 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical